BiotechTube
Hexamer Therapeutics

Hexamer Therapeutics

Cambridge, United States· Est.
hexamertherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Hexamer Therapeutics is a private, pre-clinical stage biotech developing a next-generation, self-assembling peptide vaccine platform. The technology is designed for rapid engineering and scalability, targeting both mutating infectious diseases (SARS-CoV-2) and personalized cancer vaccines. The company is led by a seasoned team with deep experience in genomics, vaccine development, and cancer research, and has secured non-dilutive funding from the US Army for its infectious disease program.

Infectious DiseaseOncology

Technology Platform

Proprietary modular platform for self-assembling peptide vaccines using natural amino acids. Features rapid engineering (candidate in 7 days), high scalability, room-temperature stability, and is combined with a safe adjuvant and AI for target design.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The urgent need for rapid-response pandemic platforms and the growing field of personalized cancer vaccines present massive market opportunities.
Government funding for biosecurity and the high unmet need in metastatic cancers provide potential non-dilutive capital and clear clinical pathways.

Risk Factors

The unproven nature of its pre-clinical platform carries high technological risk.
The company operates in extremely competitive fields against large, resource-rich players.
As a small, private firm, it faces significant execution and financial risks in advancing to clinical trials.

Competitive Landscape

In infectious diseases, Hexamer competes with mRNA giants (Moderna, Pfizer/BioNTech) and other next-gen platform companies. In cancer vaccines, it faces well-funded neoantigen players like BioNTech, Moderna, and Gritstone. Differentiation relies on the speed, scalability, and simplicity of its peptide-based platform.

More companies in Biologics / Biosimilars →More companies in United States →